Knee OA drug combo study halted early – what we know
NCT ID NCT04814368
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested two drugs, canakinumab and LNA043, injected into the knee to see if they could ease pain and protect cartilage in people with knee osteoarthritis. It included 23 adults with moderate to severe knee pain. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Res Of W Florida
Clearwater, Florida, 33765, United States
-
Horizon Clinical Research
La Mesa, California, 91942, United States
-
LV Research
Las Vegas, Nevada, 89119, United States
-
Lucas Research
Morehead City, North Carolina, 28557, United States
-
Novartis Investigative Site
Prague, Czech Republic, 19000, Czechia
-
Novartis Investigative Site
Tartu, 50406, Estonia
-
Novartis Investigative Site
Kecskemét, Bács-Kiskun county, 6044, Hungary
-
Novartis Investigative Site
Budapest, 1036, Hungary
-
Novartis Investigative Site
Riga, 1005, Latvia
-
Novartis Investigative Site
Warsaw, 02-677, Poland
-
Precision Clinical Research LLC
Sunrise, Florida, 33351, United States
Conditions
Explore the condition pages connected to this study.